---
title: First-line immunotherapy for lung cancer with MET exon 14 skipping and the
  relevance of TP53 mutations
date: '2024-01-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38271745/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240126170722&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: CHT-IO is superior to CHT, and IO alone also effective for
  METΔ14ex NSCLC, especially in the presence of TP53 mutations and independent of
  PD-L1 expression, but never-smokers are at higher risk of primary ...'
disable_comments: true
---
CONCLUSION: CHT-IO is superior to CHT, and IO alone also effective for METΔ14ex NSCLC, especially in the presence of TP53 mutations and independent of PD-L1 expression, but never-smokers are at higher risk of primary ...